上海莱士(002252) - 2014 Q4 - 年度业绩预告

Financial Performance - The net profit attributable to shareholders for 2014 is expected to increase by 250% to 260%, compared to a profit of 143.79 million yuan in the previous year[3] - The company previously estimated a net profit increase of 220% to 250% in its Q3 2014 report[3] Acquisition - The acquisition of 89.77% of Tonglu Biological Pharmaceutical Co., Ltd. was completed in December 2014, which was not included in the previous profit estimates[4] Financial Review and Disclosure - The financial data provided is subject to review by registered accountants, with the final figures to be disclosed in the annual report on February 13, 2015[5] - The company expressed apologies for any inconvenience caused by the performance forecast revision and advised investors to exercise caution[5]